Freenome (NASDAQ:FRNM) Upgraded to Strong-Buy at TD Cowen

TD Cowen upgraded shares of Freenome (NASDAQ:FRNM – Free Report) to a strong-buy rating in a report issued on Tuesday,Zacks.com reports.

A number of other equities analysts also recently issued reports on the company. BTIG Research assumed coverage on Freenome in a research report on Monday. They set a “buy” rating and a $17.00 price target on the stock. Jefferies Financial Group initiated coverage on shares of Freenome in a research report on Monday. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Leerink Partners started coverage on shares of Freenome in a research report on Friday, August 14th. They set an “outperform” rating and a $18.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $17.25.

Get Freenome alerts:

View Our Latest Report on Freenome

Freenome Trading Up 1.3%

FRNM stock opened at $13.63 on Tuesday. The firm has a market capitalization of $111.22 million, a PE ratio of -227.13 and a beta of 0.35. Freenome has a 12 month low of $9.97 and a 12 month high of $14.26.

Freenome Company Profile

(Get Free Report)

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.

See Also

• Five stocks we like better than Freenome
• Bloom Energy’s AI Surge Meets a Valuation Reality Check
• Target Is Winning Shoppers Back—Can the Rally Reach $180?
• IonQ’s Space Contract Points to a New Frontier for Quantum Investors
• Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.